# A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma

> **NCT04670055** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Zhejiang University** · enrollment: 50 (estimated)

## Conditions studied

- Relapse Multiple Myeloma
- Refractory Multiple Myeloma

## Interventions

- **DRUG:** BCMA Targeted CAR T-cells

## Key facts

- **NCT ID:** NCT04670055
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2021-01-01
- **Primary completion:** 2024-01-01
- **Final completion:** 2027-01-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2020-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04670055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04670055, "A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04670055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*